Caris Life Sciences (CAI)
Delivers tissue and blood molecular profiling for oncology care and biopharma research.
Something off on this page? Send us feedback.
Combines tissue and blood molecular profiling with sequencing, AI/ML, and a clinico-genomic dataset. MI Profile and Caris Assure serve clinical oncology, while biopharma clients use testing, data and bioinformatics, and discovery services.
MI Profile provides tissue-based molecular profiling, while Caris Assure provides blood-based profiling for oncology. Sequencing, AI/ML, and a clinico-genomic dataset sit behind the platform’s clinical molecular-profiling services.
Biopharma clients use Caris for testing, data and bioinformatics, and discovery work. Operations extend from Irving to locations in Phoenix, New York, Cambridge, Basel, and Tokyo, connecting a clinical portfolio with biopharma services.
Founded in 2008 through the acquisition of Molecular Profiling Institute, the business remains founder-led by David Dean Halbert. Its precision-medicine platform combines molecular information with AI/ML for oncology-focused clinical and biopharma use.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | UBS | Initiate | Rating: —Target: — | Target: $28 |
| Aug 7, 2026 | BTIG | Reiterate | Rating: —Target: $32 | Target: $33 |
| Aug 6, 2026 | Evercore ISI | Reiterate | Rating: —Target: $25 | Target: $26 |
| Jul 6, 2026 | Evercore ISI | Target | Target: $38 | Target: $25 |
| May 8, 2026 | Robert W. Baird | Target | Target: $26 | Target: $22 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $793.1M · Total debt $452.4M · Total assets $1.23B · Shareholders' equity $591.7M
- Revenue
- $263.7M
- Operating income
- $26.9M
- Net income
- −$637.0K
No dividends on record.
| Institutions | ≈ 54.11% | 152.91M shares | |
|---|---|---|---|
| 257 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 54.97% | 155.33M shares | |
| 15 holders · as of Sep 17, 2026 | |||
| Strategic holders | 14.62% | 41.33M shares | |
| 2 holders · as of Jun 23, 2025 | |||
| Adds to | 123.70% | ||
282.60M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 123.70%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
David D. HalbertInsiderdirector, 10 percent owner, officer: See Remarks | 43.74% | 123.60M | filed May 18, 2026 |
FMR LLCInstitution | 10.94% | 30.92M | as of Jun 30, 2026 |
TSSP Sub-Fund HoldCo LLC1Strategicother: Former 10% Owner | 8.63% | 24.39M | filed Jun 23, 2025 |
H. Whitney VI L. P. J.2Insider10 percent owner | 6.46% | 18.26M | filed May 12, 2026 |
ADAPT I Ltd.Strategic10 percent owner | 6.00% | 16.94M | filed Jun 23, 2025 |
- Reported at 4.80% on May 12, 2026, under the 5% line, so no further filing is required.
- H. Whitney VI L. P. J.'s own ownership statement (13G, May 12, 2026) reports fewer shares than the transaction reports; the statement is used.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 17, 2026 | Brian J. Brille | director, officer: See Remarks | −400,000 | $30.33 |
| Sep 4, 2026 | David Baxley Spetzler | officer: President | −119,212 | $24.76 |
| Sep 3, 2026 | David Baxley Spetzler | officer: President | −478,000 | $24.86 |
| May 15, 2026 | Jon Halbert | director | +68,000 | $14.56 |
| May 11, 2026 | Jeff L. Vacirca | director | +31,050 | $16.15 |
- Tempus AI
Genomic profiling, liquid biopsy, MRD, and AI/data services
- Guardant Health
Blood-based oncology profiling, monitoring, screening, and biopharma data
- Natera
ctDNA MRD testing and precision-medicine diagnostics
- GRAIL
Multi-cancer early detection from a blood draw
- NeoGenomics
Oncology diagnostics spanning NGS profiling, liquid biopsy, and MRD
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Caris Life Sciences | $31.72 | +3.50% | $8.66B | 85.6 | 126.0 | 8.8 | +45.4% |
| Tempus AI | $76.83 | −1.54% | $13.67B | — | — | 9.5 | +21.6% |
| Guardant Health | $177.11 | +1.86% | $23.33B | — | — | 19.7 | +44.3% |
| Natera | $386.55 | +4.29% | $53.08B | — | — | 19.6 | +37.7% |
| GRAIL | $107.16 | −0.75% | $4.63B | — | — | 28.0 | +25.7% |
| NeoGenomics | $19.07 | −1.74% | $498.7M | — | 68.6 | 0.7 | +11.2% |
| Median | — | 68.6 | 19.6 | +25.7% |